19. INFANTS WHO RECEIVED MORE VACCINES HAD MUCH HIGHER HOSPITALIZATION AND DEATH RATES THAN INFANTS WHO RECEIVED FEWER VACCINES

Relative trends in hospitalizations and mortality among infants by the number of vaccine doses and age, based on the Vaccine Adverse Event Reporting System (VAERS), 1990-2010 Human and Experimental Toxicology, 2012, GS Goldman, NZ Miller

Summary: "The hospitalization rate increased linearly from 11.0% (107 of 969) for 2 doses to 23.5% (661 of 2817) for 8 doses and decreased linearly from 20.1% (154 of 765) for children aged < 0.1 year to 10.7% (86 of 801) for children aged 0.9 year. Our findings show a positive correlation between the number of vaccine doses administered and the percentage of hospitalizations and deaths. Since vaccines are given to millions of infants annually, it is imperative that health authorities have scientific data from synergistic toxicity studies on all combinations of vaccines that infants might receive. Finding ways to increase vaccine safety should be the highest priority."

20. ISRAELI SCIENTISTS EXPLAIN ROLE VACCINE ADJUVANTS (ALUMINUM) ARE PLAYING IN AUTOIMMUNE DISEASES

The spectrum of ASIA: 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants' Lupus, 2012, N Agmon-Levin, GRV Hughes, Y Shoenfeld

Summary: "It seems that the role of adjuvants [aluminum in vaccines] in the pathogenesis of immune-mediated diseases can no longer be ignored, and the medical community must look towards producing safer adjuvants. Another cornerstone of ASIA is the complex interaction between autoimmunity and adjuvanted vaccines. On the one hand vaccines are beneficial for the vast majority of subjects including those who suffer from autoimmune-rheumatic diseases as delineated in this issue by van Assen and Bijl.16 On the other hand in a small minority of individuals vaccine can trigger the appearance of autoan- tibodies as documented by Vista et al.17 and Perdan-Pirkmajer et al.18 Moreover, a link between immunization and defined autoimmune diseases has been reported elsewhere and herein."

21. POLISH SCIENTISTS PROPOSE NEW VACCINE SCHEDULE, EXPRESS CONCERN AT HIGH RATE OF VACCINE ADVERSE EVENTS

Neurologic adverse events following vaccination Prog Health Sci, 2012, Sienkiewicz D., Ku?ak W., Okurowska-Zawada B., Paszko-Patej G.

Summary: "Thus, it is not reasonable to assume that manipulation of the immune system through an increasing number of vaccinations during critical periods of brain development will not result in adverse neurodevelopmental outcomes. European countries have different models of vaccination that have been modified in recent decades. In Scandinavian countries, which have the lowest infant mortality, vaccinations are voluntary and infants receive their first vaccination at 3 months of age. In the first year of life, they receive 9 recommended vaccinations, and at 18 months - MMR. The acellular pertussis vaccine (DTaP) is used, as well as IPV. BCG and Hepatitis B vaccines are administered to children from high risk groups. Similar vaccination schedules exist in other European countries, where the vaccination of neonates was abandoned and a ban on the use of thimerosal in vaccines was introduced. Note also that Scandinavian countries have the lowest rates of autism compared to other developed countries in which children are vaccinated much earlier and with greater number of vaccines."

22. CANADIAN RESEARCHERS REVIEW LITERATURE ON AUTOIMMUNITY AND NEUROLOGICAL RISKS FROM VACCINE ADJUVANT ALUMINUM, EXPRESS DOUBTS REGARDING SAFETY TESTING

Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations, Lupus, 2012, L Tomljenovic, CA Shaw

Summary: "Immune challenges during early development, including those vaccine-induced, can lead to permanent detrimental alterations of the brain and immune function. Experimental evidence also shows that simultaneous administration of as little as two to three immune adjuvants can overcome genetic resistance to autoimmunity. In spite of the widespread agreement that vaccines are largely safe and serious adverse complications are extremely rare, a close scrutiny of the scientific literature does not support this view. For example, to date, the clinical trials that could adequately address vaccine safety issues have not been con- ducted (i.e., comparing health outcomes in vaccinated versus non-vaccinated children). Infants and young children should not be viewed as ''small adults.'' Their unique physiology makes them much more vulnerable to noxious environ- mental insults in comparison with the adult population. In spite of this, children are routinely exposed to much higher levels of Al vaccine adjuvants than adults, even though adequate safety data on these compounds are lacking. That Al vaccine adjuvants can induce significant autoimmune conditions in humans can hardly be disputed, although still debatable is how common such side effects are. However, the existing data (or lack thereof) raise questions on whether the current vaccines aimed at pediatric populations can be accepted as having adequate safety profiles. Because infants and children represent those who may be most at risk for complications following vaccination, a more rigorous evaluation of potential vaccine-related adverse health impacts in pediatric populations than what has been provided to date is urgently needed."

23. DANISH RESEARCHERS FOUND CHILDREN 8-TIMES MORE LIKELY TO HAVE A FEBRILE SEIZURE ON THE DAY OF VACCINATION OF DTAP-IPV-HIB VACCINE

Risk of Febrile Seizures and Epilepsy After Vaccination With Diphtheria, Tetanus, Acellular Pertussis, Inactivated Poliovirus, and Haemophilus Influenzae Type b JAMA 2012, Yuelian Sun, Jakob Christensen, Anders Hviid, Jiong Li

Summary: "DTaP-IPV-Hib vaccination was associated with an increased risk of febrile seizures on the day of the first 2 vaccinations given at 3 and 5 months."